Form 8-K - Current report:
SEC Accession No. 0001213900-25-087950
Filing Date
2025-09-16
Accepted
2025-09-16 09:03:20
Documents
12
Period of Report
2025-09-10
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0257502-8k_neuphoria.htm   iXBRL 8-K 28787
  Complete submission text file 0001213900-25-087950.txt   193032

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE neup-20250910.xsd EX-101.SCH 3026
3 XBRL LABEL FILE neup-20250910_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE neup-20250910_pre.xml EX-101.PRE 22366
14 EXTRACTED XBRL INSTANCE DOCUMENT ea0257502-8k_neuphoria_htm.xml XML 3565
Mailing Address 100 SUMMIT DR BURLINGTON MA 01803
Business Address 100 SUMMIT DR BURLINGTON MA 01803 781-439-5551
Neuphoria Therapeutics Inc. (Filer) CIK: 0001191070 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-41157 | Film No.: 251315978
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)